[1］ Riska A, Leminen A ，Pukkala E.Sociodemographic determinants of incidence of primary fallopian tube carcinoma, Finland 1953-97[J]. Int J Cancer, 2003,104: 643-645.

[2］ Nik NN, Vang R, Shih IM, et al. Origin and pathogenesis of pelvic (ovarian, tubal, and primary peritoneal) serous carcinoma[J]. Annu Rev Pathol，2013 [Epub ahead of print].

[3］ Chang SJ, Bristow RE, Ryu HS.Prognostic significance of systematic lymphadenectomy as part of primary debulking surgery in patients with advanced ovarian cancer[J]. Gynecol Oncol，2012, 126: 381-386.

[4］ Luyckx M, Leblanc E, Filleron T, et al. Maximal cytoreduction in patients with figo stage Ⅲc to stage Ⅳ ovarian, fallopian, and peritoneal cancer in day-to-day practice: a retrospective french multicentric study[J]. Int J Gynecol Cancer，2012, 22(8): 1337-1343.

[5］ National Comprehensive Cancer Network. NCCN Clinical Practice Guidelines in Oncology-Ovarian Cancer (Including Fallopian Tube Cancer and Primary Peritoneal Cancer) Version 2.2013. OV-A

[6］ Deffieux X, Morice P, Thoury A, et al. [Pelvic and para-aortic lymphatic involvement in tubal carcinoma: topography and surgical implications] [J]. Gynecol Obstet Fertil, 2005, 33: 23-28.

[7］ Park JY, Kim DY, Suh DS, et al. Comparison of laparoscopy and laparotomy in surgical staging of early-stage ovarian and fallopian tubal cancer[J]. Ann Surg Oncol,2013, 15(7):2012-2019.

[8］ Brockbank EC, Harry V, Kolomainen D,et al. Laparoscopic staging for apparent early stage ovarian or fallopian tube cancer. First case series from a UK cancer centre and systematic literature review[J]. EJSO, 2013,39: 912-917.

[9］ Vergote I, Trope CG, Amant F, et al. Neoadjuvant chemotherapy or primary surgery in stage ⅢC or Ⅳ ovarian cancer[J]. N Engl J Med, 2010, 363: 943-953.

[10］ Worley MJ Jr, Guseh SH, Rauh-Hain JA,et al. Does neoadjuvant chemotherapy decrease the risk of hospital readmission following debulking surgery? [J].Gynecol Oncol, 2013, 129: 69-73.